Fmr LLC Reduces Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Fmr LLC lessened its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 62.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,024,583 shares of the company’s stock after selling 1,708,879 shares during the period. Fmr LLC’s holdings in Lyell Immunopharma were worth $1,414,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. TD Asset Management Inc lifted its stake in shares of Lyell Immunopharma by 4.2% in the 2nd quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after purchasing an additional 40,800 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Lyell Immunopharma by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after purchasing an additional 38,487 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Lyell Immunopharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after purchasing an additional 69,712 shares during the last quarter. GSA Capital Partners LLP lifted its stake in shares of Lyell Immunopharma by 1,285.5% in the 3rd quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock valued at $490,000 after purchasing an additional 329,205 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Lyell Immunopharma by 18.1% in the 2nd quarter. American Century Companies Inc. now owns 279,425 shares of the company’s stock valued at $405,000 after purchasing an additional 42,752 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LYEL. Bank of America lowered Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price target for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Trading Down 11.4 %

LYEL opened at $0.67 on Monday. The firm has a market cap of $196.86 million, a price-to-earnings ratio of -0.85 and a beta of -0.45. The stock’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.43. Lyell Immunopharma, Inc. has a 12-month low of $0.65 and a 12-month high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The company had revenue of $0.03 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, research analysts forecast that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.